The existence of a history of myocardial infarction (MI) in patients with angina pectoris is frequently associated with certain patient characteristics, including an established history of coronary artery disease (CAD), depressed left ventricular function in some patients and multivessel coronary disease.
Introduction
Angina pectoris and myocardial infarction (MI) are among the most frequently observed aspects of coronary artery disease (CAD) and in some patients these two complications may occur successively. It has been reported that half of the patients with MI will have angina pectoris during follow-up [1~71 , while databases from some studies show that, on average, half of the patients with angina pectoris have a history of MI (Table 1) .
Among these patients, some have had an MI very recently and this early post-infarction angina is an acute form of CAD that poses specific problems in terms of investigation and therapeutic approach' 1 ''. However, in this review, the objective is to focus only on patients with angina pectoris and history of a previous MI (at least 1 month before).
Three questions remain to be answered: (1) what are the main characteristics of these patients with angina pectoris and a history of MI; (2) what is the prognosis related to these characteristics; (3) what is the best therapeutic approach with regard to investigation, revascularization procedures and medical therapy? 8 ' ECSSG [9) VA study" 
Characteristics of patients
Patients with angina pectoris and a history of MI have some special characteristics. For example, the risk of recurrence of angina pectoris after MI is increased by 50% (79% vs 52%, P<001) [3] in patients who have a previous history of angina. It has also been shown that recurrent angina after MI is more common in patients with non-Q wave infarction 112 \ in whom the risk is increased by 40% (65% vs 46%, P<00001).
Furthermore, it has been shown that angina pectoris is more frequently observed in the follow-up after MI in patients with two-(68%) or three-vessel disease (77%) than in patients with one-vessel disease (36%, i'<0025). This risk is also increased in patients with proximal left anterior descending (LAD) lesions 131 . On average, patients post-MI usually exhibit some degree of depressed left ventricular function, proportionally related to the extent of necrosis, but such differences do not appear to be linked to the presence or absence of angina pectoris'
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. Furthermore, it has been shown that left ventricular function in patients with one healed MI did not differ between patients with or without exercise-induced angina pectoris and ST depression during exercise testing 1 ' 31 . In summary, the existence of a history of MI in patients with angina pectoris is frequently associated with certain patient characteristics, including an established history of CAD, depressed left ventricular function in some patients and multi-vessel disease.
Prognosis
Angina pectoris is a symptom revealing the persistence or the recurrence of myocardial ischaemia after MI. However, many studies have demonstrated that myocardial ischaemia is mostly asymptomatic and is four-times more frequent than symptomatic disease'
141
. Therefore, assessment of the prognosis of patients with angina pectoris and a history of MI is more accurately addressed by evaluating the importance of myocardial ischaemia itself. This can be done by any non-invasive investigation routinely used for detection of myocardial ischaemia, of which exercise testing is the most frequently performed. In 1979, Theroux et a/.' 151 reported that the presence of ST depression during an early exercise test after MI was predictive of subsequent cardiac events. Since then, many studies have been performed to assess the predictive value of exerciseinduced ischaemia soon after MI, often with negative results' 16 '. The presence of ischaemic episodes on 24-h ambulatory ECG monitoring has been shown to predict cardiac events' 171 , but those events which are predicted are often 'soft' events, such as coronary angioplasty (PTCA) or coronary artery bypass surgery (CABG), and not 'hard' events, such as death or recurrent MI. More recent studies, using left ventricular contraction abnormalities detected by echocardiography as a marker of ischaemia, have shown interesting results as regards prognosis evaluation' 181 . In one study, the clinical outcome was predicted with a good sensitivity (80%) and a high specificity (95%). However, in general, the presence of angina pectoris and, above all, myocardial ischaemia after MI, is a controversial prognostic factor, with probably little predictive value of death and recurrent MI.
If the prognostic value of myocardial ischaemia is unclear, left ventricular function is definitely an important prognostic indicator. Cardiac mortality in the first year after MI is directly related to left ventricular ejection fraction ( 
Treatment of angina pectoris after myocardial infarction

Medical treatment
Routine background medical treatment post-MI is now well established and many classes of drugs have a beneficial effect on the long-term prognosis and symptoms of these patients' 201 . /?-blockers, anti-platelet agents, anti-coagulants and cholesterol-lowering agents have proven efficacy in secondary prevention (Table 2) . To these drugs, cardiac rehabilitation must be added as being a beneficial treatment in post-MI patients' 201 . On the other hand, class-I anti-arrhythmics have a detrimental effect' Among the different drugs which may be prescribed in post-MI patients, particularly in cases of recurrent angina pectoris, the position of calcium channel blockers is questionable. Although their anti-anginal efficacy is proven, no overall beneficial influence on long-term prognosis has been demonstrated' 201 . But this effect differs according to the type of agent which is used' 231 . The analysis of the different published trials (Table 3) shows a trend in favour of agents that decrease heart rate (diltiazem and verapamil) in terms of longterm mortality (risk ratio: 0-95, 95% confidence interval: 0-82-1 09, ns) and reinfarction rate (risk ratio: 0-79, 95% confidence interval: 0-67-0-94, /><001). However, agents such as some dihydropyridines that increase heart rate have been shown to be associated with a non-significant trend towards a detrimental effect on Within calcium channel blockers, agents which decrease heart rate have no effect' 241 or even a slightly detrimental effect [25] on long-term prognosis in patients with congestive heart failure.
The presence of angina pectoris in patients with a history of MI suggests that the routine background treatment is insufficient. In these conditions many antianginal drugs may be of benefit in controlling symptoms, as well as myocardial ischaemia. Among these, nitrates, especially long-acting nitrates, or calcium antagonists may be prescribed, usually on top of optimal /?-blocker background treatment. Long-acting nitrates are an interesting alternative which are widely used, especially with /?-blockers, for the treatment of angina pectoris. However, reductions in efficacy have been demonstrated in long-term therapy, due to the appearance of nitrate tolerance'
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. Therefore, the control of symptoms in these patients is often based on additional treatment with calcium antagonists. Of these agents, amlodipine' 271 ( Fig. 2 ) and verapamil' 71 ( Fig. 3 ) have proven symptomatic efficacy in this population of patients. It has also been demonstrated that calcium antagonists are efficient in reducing the frequency of silent ischaemic episodes. Furthermore, they have complementary effects when associated with /J-blockers, since the latter are effective for the treatment of ischaemic episodes associated with an increase in heart rate, while calcium antagonists are more effective for ischaemic episodes not related to such an increase' 281 . They may be used in addition to /?-blockers or as monotherapy, when /?-blockers are contra-indicated. In the latter case, the choice of the calcium antagonist must be based on its impact on long-term prognosis. Although diltiazem has been shown to result in a reduction in cardiac events for a period of between 12 and 52 months post-MI, this was counter balanced by an increase in such events in those patients with left ventricular dysfunction'
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. Therefore, the only drug of this class to have proven efficacy at this time is verapamil.
In the case of an addition to ^-blockers, no data are available on the potential effects of combination therapy on prognosis. However, it may be supposed that y?-blockers and calcium antagonists with negative chronotropic action, and perhaps those with no effect on heart rate, have a beneficial additive effect on prognosis. However, key limiting factors in long-term therapy are the additive effects of both classes of drugs on contractility, heart rate (for those with a negative chronotropic effect), blood pressure and atrioventricular conduction, which should lead to some caution in initiating and continuing such combination treatment because of the high frequency of impaired left ventricular function in post-MI patients. Calcium antagonists have another interesting effect in patients with angina pectoris who are likely to have a depressed myocardial function, in that it has been shown that they may improve diastolic function' 291 , which is often altered in patients with CAD.
Thus, the medical treatment of angina pectoris in patients with a history of MI may include nitrates or calcium antagonists on top of the background treatment (usually including /?-blockers) that is routinely prescribed post-MI. In terms of being effective both on symptoms and prognosis, the best choice is a calcium antagonist with a negative chronotropic effect (or, at least, no positive chronotropic effect), although one must be cautious about the additive effects of both classes of drugs on the myocardium. In case of contraindication to /?-blockers, verapamil has proven symptomatic and prognostic efficacy when left ventricular systolic function is not depressed. However, while calcium antagonists have a beneficial effect on symptoms, there is no evidence at the present time that any drugs of this class have a beneficial effect on prognosis.
Revascularization procedures
No specific data concerning the prognostic influence of myocardial revascularization for angina pectoris after MI in large populations are available. However, large trials comparing medical and surgical treatment in patients with angina pectoris include a significant proportion of patients with a history of MI and this enables us to draw some conclusions. From these data it has been proven that patients who may benefit from aortocoronary bypass surgery include those with an ejection fraction <0-50'
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, patients with two-or three-vessel disease, including proximal LAD lesions' 91 and patients with left main coronary artery lesions' 101 . Even if these results do not exclusively concern patients with a history of MI, they may be the basis of a routine approach towards angina pectoris in patients with a history of MI. The first step in such a therapeutic approach is to perform coronary angiography and then to refer patients to surgery if coronary artery lesions and left ventricular function indicate that this is appropriate.
PTCA represents an alternative means of myocardial revascularization but it is contra-indicated in some cases, such as left main stenosis. It is also less likely to obtain complete revascularization than surgery in multivessel disease and its usefulness is limited by the restenosis rate. PTCA also suffers from the lack of data, based on large populations, regarding the possible beneficial effect of revascularization on long-term prognosis in post-MI patients' 301 . Even if the concept of an 'open artery' is interesting, no data are available regarding the value of re-opening the infarct-related artery in post-MI patients. The only clear indication for PTCA is the persistence of symptoms of angina pectoris, in spite of optimal anti-anginal therapy associated with one-or two-vessel disease and nearly normal left ventricular function.
In summary, the presence of angina pectoris in patients with a history of MI is an indication first to perform coronary artery angiography, due to the high incidence of two-or three-vessel disease and depressed left ventricular function in this population. The decision as to whether to undertake revascularization and the choice of method used should be based on the extent of coronary artery lesions and left ventriculography, together with findings from clinical and non-invasive investigations.
Medical anti-anginal therapy for symptoms, added to routine background treatment, is indicated when the results of revascularization are unsatisfactory or if there is an absence of indication or a contraindication for revascularization procedures.
Conclusions
Patients with angina pectoris and a history of MI are likely to have a history of previous angina pectoris or a history of non-Q-wave MI and often have two-or threevessel disease and depressed left ventricular function.
Despite the fact that the presence of symptoms or the persistence of myocardial ischaemia after MI has a questionable effect on long-term prognosis, there is an accumulation of data suggesting that they have little impact on subsequent cardiac 'hard' events.
The best therapeutic approach to these patients, based on the main characteristics of this population, is Angina pectoris in patients with MI 29 to perform coronary artery angiography followed by revascularization by CABG or PTCA, if necessary, according to the extent of lesions and symptoms and to add long-acting nitrates or calcium antagonists to the usual background /?-blocker treatment, paying particular attention to the possible additive negative inotropic or chronotropic effects of /?-blockers and calcium antagonists on the myocardium. If yS-blockers are contraindicated, calcium antagonists which have a proven beneficial effect on symptoms and long-term prognosis should be used.
